US 11,723,982 B2
Methods of treating an ocular disease or disorder
Kevin E. Healy, Moraga, CA (US); Eda Isil Altiok, Berkeley, CA (US); David V. Schaffer, Danville, CA (US); and Wesley M. Jackson, Albany, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Aug. 5, 2020, as Appl. No. 16/985,522.
Application 16/985,522 is a continuation of application No. 15/781,395, granted, now 10,765,759, previously published as PCT/US2016/065653, filed on Dec. 8, 2016.
Claims priority of provisional application 62/265,293, filed on Dec. 9, 2015.
Prior Publication US 2021/0113702 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 47/50 (2017.01); C07K 16/22 (2006.01); A61K 47/61 (2017.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 9/06 (2006.01); A61K 38/17 (2006.01); A61K 47/69 (2017.01); A61K 38/43 (2006.01); A61K 39/00 (2006.01)
CPC A61K 47/61 (2017.08) [A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 38/16 (2013.01); A61K 38/177 (2013.01); A61K 38/179 (2013.01); A61K 38/1774 (2013.01); A61K 38/43 (2013.01); A61K 39/3955 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/6903 (2017.08); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/35 (2013.01); C07K 2317/622 (2013.01)] 16 Claims
 
1. A method of treating an ocular disease or disorder in an individual, the method comprising administering to the individual an effective amount of a conjugate comprising:
a) a biologically active polypeptide having a molecular weight of from about 5 kDa to about 2000 kDa, wherein the biologically active polypeptide comprises an antibody specific to vascular endothelial growth factor (VEGF); and
b) a biocompatible polymer having a molecular weight of from about 500 kDa to about 1 MDa,
wherein the polypeptide is covalently linked to the polymer directly or via a linker, and wherein the molar ratio of the biologically active polypeptide to the polymer is at least 25:1,
wherein said administering is by intravitreal administration.